Vaccine Therapy in Treating Patients With Liver Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 31, 1999

Primary Completion Date

May 31, 2002

Study Completion Date

June 30, 2002

Conditions
Liver Cancer
Interventions
BIOLOGICAL

AFP gene hepatocellular carcinoma vaccine

"Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.~Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug"

Trial Locations (1)

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT00005629 - Vaccine Therapy in Treating Patients With Liver Cancer | Biotech Hunter | Biotech Hunter